ArticleAnnals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology2021
Serum insulin-like growth factor-1, asthma, and lung function among British adults.
Article in Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 13 citations in OpenAlex.
- Biomarkers of Treatment-Escalation Risk by Obesity Status in Pediatric Asthma: A Development and External Validation Cohort Study.Children (Basel, Switzerland) · 2026Article
- The implication of infection with respiratory syncytial virus in pediatric recurrent wheezing and asthma: knowledge expanded post-COVID-19 era.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024Review
- Higher levels of insulin-like growth factor-1 in cord blood associate with risk of asthma at age 3.Pediatric pulmonology · 2024Article
- The role of rhIGF-1/BP3 in the prevention of pulmonary hypertension in bronchopulmonary dysplasia and its underlying mechanism.BMC pulmonary medicine · 2023Article
- Fungal Aeroallergens-The Impact of Climate Change.Journal of fungi (Basel, Switzerland) · 2023Review
- Circulating insulin-like growth factor-1 and risk of lung diseases: A Mendelian randomization analysis.Frontiers in endocrinology · 2023Article
- The Role of Insulin Receptor Substrate Proteins in Bronchopulmonary Dysplasia and Asthma: New Potential Perspectives.International journal of molecular sciences · 2022Review
- Combined resistance and aerobic training improves lung function and mechanics and fibrotic biomarkers in overweight and obese women.Frontiers in physiology · 2022Article
- Welch-weighted Egger regression reduces false positives due to correlated pleiotropy in Mendelian randomization.American journal of human genetics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundInsulin-like growth factor-1 (IGF-1) plays a key role in the pathogenesis of metabolic syndrome, which is in turn associated with asthma. Whether IGF-1 contributes to asthma causation or asthma severity is largely unknown.
objectiveTo evaluate the relation between serum IGF-1 and asthma, asthma outcomes, and lung function in adults.
methodsCross-sectional study of 297,590 adults (aged 40-69 years) who participated in the United Kingdom Biobank, had no diagnosis of diabetes, and were not on insulin. Multivariable logistic or linear regression was used to analyze serum IGF-1 and physician-diagnosed asthma, current wheezing, asthma hospitalizations, and lung function measures (forced expiratory volume in 1 second [FEV1], forced vital capacity [FVC], and FEV1 to FVC ratio).
resultsSerum IGF-1 levels above the lowest quartile (Q1) were significantly associated with lower odds of asthma (adjusted odds ratio for fourth quartile [Q4] vs Q1 = 0.88; 95% confidence interval [CI], 0.85-0.91). Among the participants with asthma, IGF-1 levels above Q1 were significantly associated with lower odds of current wheezing (adjusted odds ratio for Q4 vs Q1 = 0.89; 95% CI, 0.83-0.96), but not with asthma hospitalizations. Serum IGF-1 was significantly and positively associated with FEV1 (b = 20.9 mL; 95% CI, 19.1-22.7) and FVC (b = 25.6 mL; 95% CI, 23.4-27.7), regardless of an asthma diagnosis; these associations were significant in men and women, with larger estimated effects in men.
conclusionIn a large study of British adults, higher serum IGF-1 levels were associated with lower odds of asthma and current wheezing and higher FEV1 and FVC. Our findings suggest potential beneficial effects of circulating IGF-1 on asthma and asthma outcomes in adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.